Principal Financial Group
NRIX icon

Principal Financial Group’s Nurix Therapeutics NRIX Stock Holding History

Principal Financial Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,953
Closed -$190K – 2428
2024
Q1 		$190K Sell
12,953
-1,182
-8% -$12.7K ﹤0.01% 2184
2023
Q4 		$146K Sell
14,135
-1,396
-9% -$9.57K ﹤0.01% 2212
2023
Q3 		$122K Buy
15,531
+2,002
+15% +$18.3K ﹤0.01% 2250
2023
Q2 		$135K Buy
13,529
+725
+6% +$7.39K ﹤0.01% 2243
2023
Q1 		$114K Buy
12,804
+1,793
+16% +$18.7K ﹤0.01% 2287
2022
Q4 		$121K Buy
+11,011
New +$133K ﹤0.01% 2271

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Principal Financial Group's NRIX Position: Q2 2024 in Review

Principal Financial Group sold out of Nurix Therapeutics (NRIX) in Q2 2024, closing a stake of 12,953 shares — an estimated $190K sold.

Principal Financial Group first reported a position in NRIX in Q4 2022 and held it in 6 quarters. The position peaked at $190K in Q1 2024. 173 funds tracked by Wall St. Rank hold NRIX as of Q2 2024.

  • Principal Financial Group reported no remaining Nurix Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 12,953 Nurix Therapeutics shares in Q2 2024, an estimated $190K.
  • Principal Financial Group first reported a position in Nurix Therapeutics in Q4 2022 and held it in 6 quarters.
  • Principal Financial Group's Nurix Therapeutics position peaked at $190K in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.